Company Description
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
The company’s lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity.
Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 173 |
| CEO | Michel Detheux |
Contact Details
Address: 321 Arsenal Street Watertown, Massachusetts 02472 United States | |
| Phone | 339 217 0161 |
| Website | iteostherapeutics.com |
Stock Details
| Ticker Symbol | ITOS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001808865 |
| CUSIP Number | 46565G104 |
| ISIN Number | US46565G1040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer and Director |
| Matthew Gall | Chief Financial Officer |
| Matthew A. Call M.B.A. | Chief Operating Officer |
| Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer |
| Adi Osovsky | Executive Vice President of Legal |
| Philippe Brantegem | Executive Vice President of Human Resources |
| Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Nov 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |